Lidia Fonseca, senior vice president and chief information officer of Quest Diagnostics, explains where the future of data analytics is going in healthcare as the industry moves to value-based care.
Lidia Fonseca, senior vide president and chief information officer of Quest Diagnostics, explains where the future of data analytics is going in healthcare as the industry mov
Transcript (slightly modified)
As the US healthcare system moves more toward value-based care, where do you see the future of patient-specific data analytics going? And what role will they play in the changing industry?
I think when you step back and you look at what has been happening in our industry, I like to describe it as we're shifting from treating the sick to keeping people well. And in the process, information and connecting the dots about a patient becomes very, very significant in that in order to be able to keep patients well over time, it's important that we can connect the dots about them.
So where things are going is 1) being able to bring the complete record of the patient. That's one of the important steps of where we're going. The second one is being able to glean insights and then make them actionable. And we make them actionable by actually integrating them into the physician's workflow. And the third element of it is—so 1 is the complete record, 2 is make those insights actionable, and 3, make them available on demand at the point of care, because that's when it matters and that's when the physician can make the right decisions about patient care.
And that's where we see it going. It's really those 3 elements in terms of data analytics and where the industry is going as we shift to this more value-based care approach.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More